Nektar Therapeutics NKTR shares are trading higher by $5.00 (33 percent) at $20.50 in Monday's session. The catalyst for the rally is that its study for NKTR-181 has met its primary and secondary endpoints in Phase 3 Summit-07 study for chronic pain.
After a $3.00 higher opening print of $18.78, Nektar's stock had only a $0.26 pullback to $18.51 before continuing its move higher. The follow-though on the rally has taken it in the $20.00 handle for the first time since June 2006, when it peaked at $21.22. Although it did challenge the $20.00 area as early as last September, when its rally from the $10.00 area stalled at $19.98.
Today's price action is taking place on much higher than average volume. With over five hours remaining in the session, 5.4 million shares have already traded compared with its 20-day average of 1.76 million.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
